We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 526.00
Bid: 526.00
Ask: 527.00
Change: -3.00 (-0.57%)
Spread: 1.00 (0.19%)
Open: 530.00
High: 530.00
Low: 524.00
Prev. Close: 529.00
POLR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AuM Update

13 Oct 2022 07:00

RNS Number : 7235C
Polar Capital Holdings PLC
13 October 2022
 

13 October 2022 Polar Capital Holdings plc

AuM Update

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides a quarterly update of its unaudited statement of Assets under Management ("AuM").

 

 

Group AuM (unaudited)

 

Polar Capital reports that as at 30 September 2022 its AuM were £18.8bn compared to £18.9bn at the end of the June quarter and £22.1bn at the end of March 2022. During the six-month period, AuM decreased by net redemptions of £0.8bn, outflows from previously reported fund closures of £0.5bn and a £2.0bn decrease related to market movement and fund performance.

 

AuM movement in six months to 30 September 2022

Open ended

funds

Investment

Trusts

Segregated mandates

Total

AuM at 1 April 2022

£16,590m

£4,378m

£1,153m

£22,121m

Net flows

£(753)m

£(62)m

£(30)m

£(845)m

Fund closures1

£(380)m

-

£(79)m

£(459)m

Market movement

and performance

£(1,374)m

£(611)m

£(66)m

£(2,051)m

Total AuM at

30 September 2022

£14,083m

£3,705m

£978m

£18,766m

1 Return of funds to investors on closure of the Phaeacian mutual funds and related segregated mandate in Q1.

 

Net performance fees (unaudited)

 

The table below sets out the position relating to net performance fee profits due to the Group (after the deduction of staff interests) as a product of accrued performance fees in funds managed by the Group three months before the strike point of such performance fee receipts. The majority of the Group's performance fees crystallise in the second half of the financial year. There is no certainty that the fees will be sustained over the next quarter, as performance fees can be volatile.

 

Performance fees

net of staff allocations

Six months to

30 Sept 21

Year to

31 Mar 22

(year-end)

Six months to

30 Sept 22

Received

-

£4.1m

-

Accrued but not yet earned in funds with year ends on or before the financial year end

£2m

n/a

£4.8m*

Total net performance fee profits

£2m

£4.1m

£4.8m*

\* The figures have been reduced by £1.0m of net performance fee distributions that relate to prior accounting periods that IFRS require to be deducted from this year's receipts.

 

 

Gavin Rochussen, Chief Executive, commented:

 

"There has been continued demand and inflows into the Global Insurance, Biotechnology, Healthcare Blue Chip, Smart Energy, European ex-UK Income, Emerging Market Stars, Forager and Global Absolute Return Funds, with combined net inflows of £260m across these funds in the quarter.

 

"A combination of the bear market sell-off, net outflows, fund closures and fund performance meant that our AuM at the end of the six-month period were £18.8bn compared to £18.9bn at the end of the previous quarter and £22.1bn at the end of March 2022. Total net outflows for the quarter were £529m.

 

"During the quarter, the rate of outflows from the open-ended Technology funds continued to decline, with £252m of outflows compared to £380m in the previous quarter and £630m in the first quarter of this calendar year. Outflows of £250m from the UK Value Opportunities Fund during the quarter reflected client asset allocation decisions with UK equity exposure being reduced.

 

"Despite the challenging back drop, we are pleased with the continuing progress in diversifying the business. The Smart funds managed by the Sustainable Thematic team have now collectively reached £150m. The Emerging Market Stars team have had success in the US with the Emerging Market Stars Mutual Fund raising its first £50m.

 

"The well-established Polar Capital Global Insurance fund has continued to deliver robust performance with net inflows of £257m in the six months. The team's low appetite for catastrophe risk has protected investor returns with the Fund well positioned to benefit from ongoing premium rate rises in commercial insurance and a recent acceleration in reinsurance pricing. For the calendar year to September 2022, the fund has achieved absolute positive performance of 12.2% which is 6.5% ahead of its benchmark.

 

"We remain confident that with our diverse range of differentiated, active specialist fund strategies we are well-positioned to perform for our clients and shareholders over the long term."

 

 

For further information please contact:

 

Polar Capital

Gavin Rochussen (Chief Executive)Samir Ayub (Finance Director)

+44 (0)20 7227 2700

 

Numis Securities Limited - Nomad and Joint Broker

Giles Rolls

Charles Farquhar

Stephen Westgate

 

 

+44 (0)20 7260 1000

 

 

Peel Hunt LLP - Joint Broker

Andrew Buchanan

 

 

+44 (0)20 3597 8680

 

Camarco

Ed Gascoigne-Pees

Jennifer Renwick

Phoebe Pugh

 

+44 (0)20 3757 4995

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAEEDFFFAFEA
Date   Source Headline
26th Apr 202410:33 amRNSForm 8.3 - RENALYTIX PLC
17th Apr 20243:55 pmRNSDirector/PDMR Shareholding
12th Apr 20245:43 pmRNSHolding(s) in Company
11th Apr 20247:00 amRNSAuM Update
9th Apr 20244:01 pmRNSChange of Company Secretary
15th Mar 20243:02 pmRNSForm 8.3 - Renalytix PLC
15th Mar 202410:23 amRNSForm 8.3 - Renalytix PLC - Replacement
13th Mar 20246:14 pmRNSForm 8.3 - RENALYTIX PLC
7th Mar 20244:30 pmRNSHolding(s) in Company
6th Mar 20245:47 pmRNSForm 8.3 - DIRECT LINE INSURANCE GROUP PLC
6th Mar 20245:37 pmRNSForm 8.3 - RENALYTIX PLC
27th Feb 20242:19 pmRNSForm 8.3 - Wincanton PLC
7th Feb 20242:09 pmRNSDirector/PDMR Shareholding
1st Feb 20247:00 amRNSBlock listing Interim Review
25th Jan 20244:53 pmRNSForm 8.3 -Wincanton PLC
11th Jan 20247:00 amRNSAuM Update
10th Jan 20242:54 pmRNSHolding(s) in Company
10th Jan 20242:51 pmRNSHolding(s) in Company
20th Nov 20237:00 amRNSPolar Capital Holdings Unaudited interim results
9th Nov 20237:00 amRNSInvestor Presentation covering Interim Results
26th Oct 20237:00 amRNSNotice of Interim Results
12th Oct 20237:00 amRNSAuM Update
28th Sep 20235:36 pmRNSResult of AGM
18th Aug 20234:45 pmRNSDirector/PDMR Shareholding
1st Aug 202312:05 pmRNSBlock listing Interim Review
19th Jul 20234:34 pmRNSDirector/PDMR Shareholding
18th Jul 20234:30 pmRNSDirector/PDMR Shareholding
13th Jul 202311:01 amRNSDirector/PDMR Shareholding - Replacement
13th Jul 202310:48 amRNSDirector/PDMR Shareholding
13th Jul 202310:31 amRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSAuM Update
26th Jun 20233:34 pmRNSInvestor Presentation covering Full Year Results
26th Jun 20237:00 amRNSGroup Audited Results for year ended 31 March 2023
1st Jun 20237:00 amRNSTotal Voting Rights
25th May 202312:26 pmRNSIssue of Equity
10th May 20233:10 pmRNSDirector/PDMR Shareholding
21st Apr 20232:36 pmRNSHolding(s) in Company
14th Apr 20234:01 pmRNSDirector/PDMR Shareholding
13th Apr 20237:00 amRNSAuM Update
31st Mar 202312:23 pmRNSDirector/PDMR Shareholding
10th Mar 20233:17 pmRNSDirector/PDMR Shareholding
24th Feb 20235:18 pmRNSForm 8.3 - REDX Pharma PLC
16th Feb 20235:06 pmRNSDirector/PDMR Shareholding
7th Feb 202311:09 amRNSHolding(s) in Company
1st Feb 20237:00 amRNSBlock listing Interim Review
12th Jan 20237:00 amRNSAuM Update
30th Dec 20227:00 amRNSDirectorate Change
21st Nov 20227:00 amRNSUnaudited interim results
15th Nov 20227:00 amRNSInvestor Presentation covering Interim Results
24th Oct 20227:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.